Press Releases June 9, 2026 04:05 PM

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

Iridex Corporation announces participation in Planet MicroCap Las Vegas 2026 Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
IRIX

Iridex Corporation, a leader in laser-based medical systems for ophthalmology, will present at the Planet MicroCap Las Vegas 2026 Conference. The presentation is scheduled for June 17, 2026, and will be webcast on the company website. Iridex specializes in products for treating glaucoma, diabetic macular edema, and retinal diseases using their proprietary MicroPulse technology.

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
IRIX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Iridex to present at a notable microcap investor conference, enhancing exposure to potential investors.
  • Company focuses on innovative laser-based treatments for eye diseases such as glaucoma and diabetic macular edema.
  • Products are marketed worldwide, with direct US sales and international distribution through independent dealers.

MOUNTAIN VIEW, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Planet MicroCap Las Vegas 2026 Conference.

Management is scheduled to present on Wednesday, June 17 at 4:00 pm PT. Interested parties may access a live and archived webcast of the presentation on the “Event Calendar” page of the “Investors” section of the company’s website at www.IRIDEX.com.

About Iridex Corporation 
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions.  © 2026 Iridex Corporation.  All rights reserved.

Investor Relations Contact
Philip Taylor
Gilmartin Group
[email protected] 

Media Contact
Joan Stauffer
[email protected]


Risks

  • Market reception of the presentation may be limited, impacting investor interest and stock performance.
  • Competitive pressures in the ophthalmology medical device sector could affect future growth potential.
  • Regulatory challenges or delays could impact product sales, especially in international markets.

More from Press Releases

RMG ML Sports Holdings Announces the Pricing of $200 Million Initial Public Offering Jun 9, 2026 BlockchAIn Announces Closing of $55 Million Public Offering of Common Stock Jun 9, 2026 Maui Land & Pineapple Company, Inc. Appoints a Chief Investment Officer Jun 9, 2026 Applied Digital Announces Pricing of $1.59 Billion of Senior Secured Notes to fund the Fourth Building at Polaris Forge 1 Jun 9, 2026 Einride, a Global Leader in Autonomous and Electric Freight, Completes Business Combination and Will Begin Trading on Nasdaq Stock Market Jun 9, 2026